Risk Assessment in HR-Positive/HER2-Negative Breast Cancer
• Video: A Patient’s Journey With Early-Stage HR-Positive/HER2-Negative Breast Cancer
• Molecular profiling: when to test, how to test, and which patients to test
• Case discussions
Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative
Early-Stage Breast Cancer
• Novel therapies to improve outcomes for high-risk patients in the adjuvant setting
• Neoadjuvant therapy considerations
• Optimal sequencing of targeted therapy with ET and chemotherapy
• Clinical trial spotlight
Strategies for Promoting Adherence and Persistence to Oral CDK4/6 Inhibitors in Early-Stage Breast Cancer
• Proactive management of adverse events associated with CDK4/6 inhibitors
• Shared decision-making between HCPs and patients for decisions concerning targeted therapies
• HCP and patient responsibilities for oral adherence
Audience Question and Answer
Date / Time
Erika Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Drug Development Unit
Sarah Cannon Research Institute
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
US Oncology Network
The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally assess the risk of patients with HR-positive/HER2-negative early breast cancer and select optimal individualized therapy for those with higher-risk disease.
This program is intended for oncologists, pharmacists, nurse practitioners, oncology nurses, and other healthcare professionals on the multidisciplinary team who care for patients with breast cancer.
Upon completion of this activity, participants should be able to:
- Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice
- Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting
- Foster collaborative discussions and workflows between the oncology multidisciplinary team and patients to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer
- Promote strategies to ensure optimal adherence and persistence to prescribed oral CDK4/6 inhibitors in patients with early-stage breast cancer
- Manage adverse events associated with oral targeted therapy in the adjuvant setting for patients with HR-positive/HER2-negative breast cancer
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-212-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO), requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.